The venous
thromboembolism therapeutics pipeline is expected to
witness considerable growth in the coming year due to the development of novel oral
anticoagulants as a reasonable and established treatment option. The regulatory
bodies are supporting the drug development process through different types of
designations and funding. The pipeline is being driven by different factors
such as increasing awareness regarding the venous thromboembolism therapeutics pipeline,
high demand for safe, effective and affordable medications, technological
advancements and increasing prevalence of the venous thromboembolism.
Explore Report at: https://www.psmarketresearch.com/market-analysis/venous-thromboembolism-therapeutics-pipeline-analysis
According
to American Heart Association, Venous thromboembolism (VTE) collectively develops
as a combination of deep vein thrombosis (DVT) and pulmonary embolism (PE), two
life-threatening conditions. Venous thromboembolism is a common and preventable
disease in which the clot formation occurs in the vein associated with Venous
thromboembolism. In deep vein thrombosis, a clot formed in a deep vein, usually
in the leg. Pulmonary embolism is a deep vein thrombosis clot that breaks free
from a vein wall, travels to the lungs and blocks some or all of the blood
supply. Blood clots in the thigh are more likely to break off and travel to the
lungs than the clots in lower leg or other parts of the body.
Some of the companies having a pipeline of venous thromboembolism therapeutics include Bristol-Myers Squibb Company, Pfizer, Inc., Sanofi-Aventis, Daiichi Sankyo Co. Ltd., Astellas Pharma Inc. and Johnson & Johnson.
No comments:
Post a Comment